Pre-existing immunity does not impair the engraftment of CRISPR-Cas9-edited cells in rhesus macaques conditioned with busulfan or radiation

Essawi, Khaled; Hakami, Waleed; Khan, Muhammad Behroz Naeem; Reid, M M; Zeng, Jing; Chu, Rebecca; Uchida, Naoya; Krouse, Allen E.; Linde, Nathaniel S.; Donahue, Robert E.; Blobel, Gerd A.; Gerdemann, Ulrike; Kean, Leslie S.; Maitland, Stacy; Wolfe, Scot A.; Métais, Jean‐Yves; Bauer, Daniel; Tisdale, John F.; Demirci, Selami

doi:10.1016/j.omtm.2023.04.004

Cited by 4 publications

(1 citation statement)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…If necessary, multiple immunosuppressive drug treatments, including T cell-depleting regimens (approved for AAV-based therapies), are available [311][312][313][314][315]. However, some data indicate that pre-existing immunity does not impair the engraftment of CRISPR/Cas9edited cells in pre-conditioned busulfan or radiation organisms [316].…”

Section: Pre-existing Immunity Against Crispr/cas9 Proteinsmentioning

confidence: 99%

CRISPR/Cas9 Landscape: Current State and Future Perspectives

Tyumentseva,

Tyumentsev,

Akimkin

2023

IJMS

View full text Add to dashboard Cite

CRISPR (clustered regularly interspaced short palindromic repeats)/Cas9 is a unique genome editing tool that can be easily used in a wide range of applications, including functional genomics, transcriptomics, epigenetics, biotechnology, plant engineering, livestock breeding, gene therapy, diagnostics, and so on. This review is focused on the current CRISPR/Cas9 landscape, e.g., on Cas9 variants with improved properties, on Cas9-derived and fusion proteins, on Cas9 delivery methods, on pre-existing immunity against CRISPR/Cas9 proteins, anti-CRISPR proteins, and their possible roles in CRISPR/Cas9 function improvement. Moreover, this review presents a detailed outline of CRISPR/Cas9-based diagnostics and therapeutic approaches. Finally, the review addresses the future expansion of genome editors’ toolbox with Cas9 orthologs and other CRISPR/Cas proteins.

show abstract